Similar Papers

Paper Title
Journal
Date
Author
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy.
Martina Paoletti ... Francesco Saverio Mennini
Clinical drug investigation | VOL. 44
Martina Paoletti, et. al.Martina Paoletti ... Francesco Saverio Mennini
01 Aug 2024
Surgical Survival Benefits With Different Metastatic Patterns for Stage IV Extrathoracic Metastatic Non-Small Cell Lung Cancer: A SEER-Based Study.
Ce Chao ... Xiao-Ying Zhang
Technology in cancer research & treatment | VOL. 20
Ce Chao, et. al.Ce Chao ... Xiao-Ying Zhang
01 Jan 2020
A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
Michael GÖRn ... Birte Andritzky
Oncology Research and Treatment | VOL. 31
Michael GÖRn, et. al.Michael GÖRn ... Birte Andritzky
20 Mar 2008
KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer.
Ella A Eklund ... Volkan I Sayin
Cancers | VOL. 14
Ella A Eklund, et. al.Ella A Eklund ... Volkan I Sayin
20 Apr 2022
View more papers

More From: Swiss Medical Weekly

Paper Title
Journal
Date
Author
Reimbursement policies of Swiss health insurances for the surgical treatment of symptomatic breast hypertrophy: a retrospective cohort study
Astrid Navarra ... Yves Harder
Swiss Medical Weekly | VOL. -
Astrid Navarra, et. al.Astrid Navarra ... Yves Harder
24 Jan 2025
Outcomes of coronary artery aneurysms: insights from the Coronary Artery Ectasia and Aneurysm Registry (CAESAR).
Alessandro Candreva ... Christian Templin
Swiss medical weekly | VOL. 155
Alessandro Candreva, et. al.Alessandro Candreva ... Christian Templin
06 Jan 2025
Enhancing interprofessional ward rounds by identifying factors associated with low satisfaction and efficiency: a quantitative and qualitative national survey of Swiss healthcare professionals.
Armon Arpagaus ... Sabina Hunziker
Swiss medical weekly | VOL. 155
Armon Arpagaus, et. al.Armon Arpagaus ... Sabina Hunziker
06 Jan 2025
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
Tämer El Saadany ... Roger Von Moos
Swiss Medical Weekly | VOL. -
Tämer El Saadany, et. al.Tämer El Saadany ... Roger Von Moos
06 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.